Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Lazertinib |
Synonyms | |
Therapy Description |
Lazcluze (lazertinib) is an irreversible protein kinase inhibitor with selective activity against mutant EGFR, which may lead to growth inhibition of EGFR-mutant tumor cells and reduced toxicity (PMID: 30670498, PMID: 32599977). Lazcluze (lazertinib) is FDA approved in combination with Rybrevant (amivantamab-vmjw) as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 19 deletions or EGFR L858R (FDA.gov) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lazertinib | Lazcluze | GNS 1480|YH25448|JNJ-73841937|JNJ73841937|JNJ 73841937|YH 25448|YH-25448 | EGFR Inhibitor 3rd gen 26 | Lazcluze (lazertinib) is an irreversible protein kinase inhibitor with selective activity against mutant EGFR, which may lead to growth inhibition of EGFR-mutant tumor cells and reduced toxicity (PMID: 30670498, PMID: 32599977). Lazcluze (lazertinib) is FDA approved in combination with Rybrevant (amivantamab-vmjw) as first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 19 deletions or EGFR L858R (FDA.gov) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06667076 | Phase II | Lazertinib Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium | A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (COPERNICUS) | Recruiting | USA | 1 |
NCT04075396 | Phase Ib/II | Lazertinib | A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | GBR | ESP | 0 |
NCT04487080 | Phase III | Amivantamab-vmjw + Lazertinib Lazertinib Osimertinib | A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) | Active, not recruiting | USA | TUR | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 12 |
NCT04077463 | Phase I | Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Carboplatin + Lazertinib + Pemetrexed Disodium Amivantamab-vmjw Lazertinib | A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer (Chrysalis-2) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | 5 |